Pathologies and Treatments

Stargardt disease

STARGARDT

Stargardt disease is an early degeneration of the retina of genetic cause. This disease mainly affects the macula. The macula is the part of the retina responsible for central vision. This vision is what we use to read, watch television, or recognize faces.

Stargardt disease is the most common variant of inherited juvenile macular degeneration. It has an estimated prevalence of between 1 in 8,000 and 1 in 10,000. It is usually diagnosed in people under twenty years of age. However, vision loss may not be evident until the third or fourth decade of life.

Approximately 90% of cases are transmitted in an autosomal recessive manner. This means that, for a person to have this disease, both parents must carry the affected gene. In this case, the chance of having an affected child is 25%. Being a recessive gene, there may be no family history of Stargardt disease. This is because the parents are carriers of the gene but do not manifest the disease.

Symptoms

The symptoms related to Stargardt disease usually develop gradually. Children or adolescents complain that they find it difficult to read and progressively begin to notice gray or black areas (without vision) in the center of the visual field. The loss of vision is progressive and variable depending on the patients. It can lead to very severe vision loss.

The vast majority of patients do not lose peripheral and night vision, but in the late stages of the disease, color vision is also affected.

Procedures

Medicina regenerativa: Endoret

Con el tratamiento de medicina regenerativa Endoret propiciamos la reparación de la superficie ocular afectada por la sequedad ocular. Se trata de un plasma rico en factores de crecimiento para el tratamiento de las lesiones de la superficie ocular elaborado a partir de la sangre del mismo paciente. Con esta formulación individualizada se consigue una tolerancia completa y una efectividad óptima. Esta opción terapéutica revolucionaria es muy eficaz en casos de defectos epiteliales persistentes o úlceras corneales. Asimismo se puede aplicar después de una cirugía refractiva corneal, una cirugía ocular o en el Síndrome de Sjögren.

Dr. Jordi Monés,

M.D. PhD

Número de Col·legiat COMB: 22.838

Director. Doctor of Medicine and Surgery. Specialist in Ophthalmology. Specialist in Retina, Macula, and Vitreous.

If you found this interesting, feel free to share it here:

Last modified: 26/08/2025
Scroll to Top
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.